» Articles » PMID: 17299411

DJ-1 and Parkin Modulate Dopamine-dependent Behavior and Inhibit MPTP-induced Nigral Dopamine Neuron Loss in Mice

Overview
Journal Mol Ther
Publisher Cell Press
Date 2007 Feb 15
PMID 17299411
Citations 55
Authors
Affiliations
Soon will be listed here.
Abstract

Parkin-deficient animals exhibit mitochondrial degeneration and increased oxidative stress vulnerability, and both mice and flies lacking DJ-1 are hypersensitive to environmental toxins associated with Parkinson's disease (PD). We used recombinant adeno-associated virus (AAV) gene transfer to study the influence of DJ-1 and Parkin on the dopaminergic system of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice, a model for sporadic PD. After MPTP lesioning, significantly more dopamine neurons survived in the virus-injected substantia nigra of the AAV-DJ-1 and AAV-Parkin mice when compared with AAV-enhanced green fluorescent protein injected controls. Protection at the neuronal level was supported by increased amphetamine-induced contralateral turning behavior. Normal mice expressing DJ-1 showed apomorphine-induced ipsilateral turning, suggesting a hyporesponsiveness of striatal dopamine D1 receptors in the DJ-1-expressing hemisphere. MPTP drastically reduced dopamine to 19% of normal levels and neither DJ-1 nor Parkin protected against MPTP-induced catecholamine loss under these conditions. Our results show that Parkin and DJ-1 inhibit dopamine neuron death and enhance amphetamine-induced dopaminergic function in a mouse model of idiopathic PD. However, DJ-1 overexpression also reduced postsynaptic dopamine receptor responses in normal mice. These results warrant further exploration of DJ-1 and Parkin gene therapy for PD, although a better understanding of their effects on behavior and dopamine neurotransmission is required before these proteins can be safely used.

Citing Articles

17β-Trenbolone Exposure Enhances Muscle Activity and Exacerbates Parkinson's Disease Progression in Male Mice.

Zuo X, Bai H, Zhao Q, Zhang S, Zhao X, Feng X Mol Neurobiol. 2024; 62(3):3053-3066.

PMID: 39222261 DOI: 10.1007/s12035-024-04455-3.


Targeting the NRF2 pathway for disease modification in neurodegenerative diseases: mechanisms and therapeutic implications.

Mayer C, Riera-Ponsati L, Kauppinen S, Klitgaard H, Erler J, Hansen S Front Pharmacol. 2024; 15:1437939.

PMID: 39119604 PMC: 11306042. DOI: 10.3389/fphar.2024.1437939.


Novel Insights into Parkin-Mediated Mitochondrial Dysfunction and "Mito-Inflammation" in α-Synuclein Toxicity. The Role of the cGAS-STING Signalling Pathway.

Gassowska-Dobrowolska M, Olech-Kochanczyk G, Culmsee C, Adamczyk A J Inflamm Res. 2024; 17:4549-4574.

PMID: 39011416 PMC: 11249072. DOI: 10.2147/JIR.S468609.


Oxidative Stress and Antioxidants in Neurodegenerative Disorders.

Olufunmilayo E, Gerke-Duncan M, Holsinger R Antioxidants (Basel). 2023; 12(2).

PMID: 36830075 PMC: 9952099. DOI: 10.3390/antiox12020517.


Unraveling Parkinson's Disease Neurodegeneration: Does Aging Hold the Clues?.

Coleman C, Martin I J Parkinsons Dis. 2022; 12(8):2321-2338.

PMID: 36278358 PMC: 9837701. DOI: 10.3233/JPD-223363.